Cerebrovascular effects of amyloid-β peptides: Mechanisms and implications for Alzheimer's dementia

Cellular and Molecular Neurobiology

Volumn 23, Issue 4-5, 2003, Pages 681-689

  Iadecola, Costantino ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Functional hyperemia; Trangenic mice; Vascular dementia; Vascular regulation

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD PRESSURE REGULATION; BRAIN BLOOD VESSEL; BRAIN CIRCULATION; CARDIOVASCULAR RESPONSE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; ENDOTHELIUM CELL; EVOKED RESPONSE; HYPEREMIA; MOUSE; MULTIINFARCT DEMENTIA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; CEREBROVASCULAR CIRCULATION; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; VASODILATION;

ANIMALIA; MUS MUSCULUS;

EID: 0041816291     PISSN: 02724340     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025092617651     Document Type: Review

References (51)

1. Alonzo, N. C., Hyman, B. T., Rebeck, G. W., and Greenberg, S. M. (1998). Progression of cerebral amyloid angiopathy: Accumulation of amyloid-beta40 in affected vessels. J. Neuropathol. Exp. Neurol. 57:353-359.
2. Babior, B. M., Aji, W., Ravalli, S., Szabolcs, M., Jiang, X. C., Sciacca, R. R., Michler, R. E., and Cannon, P. J. (1999). NADPH oxidase: An update. Blood 93:1464-1476.
3. Behl, C., Davis, J. B., Lesley, R., and Schubert, D. (1994). Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77:817-827.
4. Bookheimer, S. Y., Strojwas, M. H., Cohen, M. S., Saunders, A. M., Pericak-Vance, M. A., Mazziotta, J. C., and Small, G. W. (2000). Patterns of brain activation in people at risk for Alzheimer's disease. N. Engl. J. Med. 343:450-456.
5. Braak, H., and Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl.) 82:239-259.
6. Brun, A., and Englund, E. (1986). A white matter disorder in dementia of the Alzheimer type: A pathoanatomical study. Ann. Neurol. 19:253-262.
7. Cai, H., Harrison, D. G., Rothe, G., and Valet, G. (2000). Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ. Res. 87:840-444.
8. Crawford, F., Suo, Z., Fang, C., and Mullan, M. (1998). Characteristics of the in vitro vasoactivity of beta-amyloid peptides. Exp. Neurol. 150:159-168.
9. Faraci, F. M., and Heistad, D. D. (1998). Regulation of the cerebral circulation: Role of endothelium and potassium channels. Physiol. Rev. 78:53-97.
10. Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., Guido, T., Hagopian, S., Johnson-Wood, K., Khan, K., Lee, M., Leibowitz, P., Lieberburg, I., Little, S., Masliah, E., McConlogue, L., Montoya-Zavala, M., Mucke, L., Paganini, L., and Penniman, E. (1995). Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373:523-527.
11. Glenner, G. G., and Wong, C. W. (1984). Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 122:1131-1135.
12. Good, P. F., Werner, P., Hsu, A., Olanow, C. W., and Perl, D. P. (1996). Evidence of neuronal oxidative damage in Alzheimer's disease. Am. J. Pathol. 149:21-28.
13. Griendling, K. K., Minieri, C. A., Ollerenshaw, J. D., and Alexander, R. W. (1994). Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74:1141-1148.
14. Hensley, K., Carney, J. M., Mattson, M. P., Aksenova, M., Harris, M., Wu, J. F., Floyd, R. A., and Butterfield, D. A. (1994). A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 91:3270-3274.
15. Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., and Cole, G. (1996). Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274:99-102.
16. Hsiao, K. K., Borchelt, D. R., Olson, K., Johannsdottir, R., Kitt, C., Yunis, W., Xu, S., Eckman, C., Younkin, S., Price, D., Iadecola, C., Clark, H. B., and Carlson, G. (1995). Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 15:1203-1218.
17. Iadecola, C., Zhang, F., Niwa, K., Eckman, C., Turner, S. K., Fischer, E., Younkin, S., Borchelt, D. R., Hsiao, K. K., and Carlson, G. A. (1999). SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat. Neurosci. 2:157-161.
18. Irizarry, M. C., McNamara, M., Fedorchak, K., Hsiao, K., and Hyman, B. T. (1997). APPSW transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol. 56:965-973.
19. Jagust, W. J., Eberling, J. L., Reed, B. R., Mathis, C. A., and Budinger, T. F. (1997). Clinical studies of cerebral blood flow in Alzheimer's disease. Ann. N. Y. Acad. Sci. 826:254-262.
20. Jagust, W. J., Haan, M. N., Reed, B. R., and Eberling, J. L. (1998). Brain perfusion imaging predicts survival in Alzheimer's disease. Neurology 51:1009-1013.
21. Kalaria, R. N. (1996). Cerebral vessels in ageing and Alzheimer's disease. Pharmacol. Ther. 72:193-214.
22. Kawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., and Younkin, S. G. (2001). Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21:372-381.
23. Le, R., Cruz, L., Urbanc, B., Knowles, R. B., Hsiao-Ashe, K., Duff, K., Irizarry, M. C., Stanley, H. E., and Hyman, B. T. (2001). Plaque-induced abnormalities in neurite geometry in transgenic models of Alzheimer disease: Implications for neural system disruption. J. Neuropathol. Exp. Neurol. 60:753-758.
24. Lee, V. M., Goedert, M., and Trojanowski, J. Q. (2001). Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24:1121-1159.
25. Levy-Lahad, E., and Bird, T. D. (1996). Genetic factors in Alzheimer's disease: A review of recent advances. Ann. Neurol. 40:829-840.
26. Loo, D. T., Copani, A., Pike, C. J., Whittemore, E. R., Walencewicz, A. J., and Cotman, C. W. (1993). Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc. Natl. Acad. Sci. U.S.A. 90:7951-7955.
27. Matsushita, K., Kuriyama, Y., Nagatsuka, K., Nakamura, M., Sawada, T., and Omae, T. (1994). Periventricular white matter lucency and cerebral blood flow autoregulation in hypertensive patients. Hypertension 23:565-568.
28. Mattson, M. P., Cheng, B., Davis, D., Bryant, K., Lieberburg, I., and Rydel, R. E. (1992). beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12:376-389.
29. Mattson, M. P. (1997). Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol. Rev. 77:1081-1132.
30. Mohazzab-H, K. M., Kaminski, P. M., and Wolin, M. S. (1994). NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am. J. Physiol. 266:H2568-H2572.
31. Niwa, K., Carlson, G. A., and Iadecola, C. (2000a). Exogenous A beta1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. J. Cereb. Blood Flow Metab. 20:1659-1668.
32. Niwa, K., Kazama, K., Younkin, S. G., Carlson, G. A., and Iadecola, C. (2002a). Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol. Dis. 9:61-68.
33. Niwa, K., Kazama, K., Younkin, L., Younkin, S. G., Carlson, G. A., and Iadecola, C. (2002b). Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am. J. Physiol. Heart Circ. Physiol. 283:H315-323.
34. Niwa, K., Porter, V. A., Kazama, K., Cornfield, D., Carlson, G. A., and Iadecola, C. (2001). Abeta-peptides enhance vasoconstriction in cerebral circulation. Am. J. Physiol. Heart Circ. Physiol. 281:H2417-H2424.
35. Niwa, K., Younkin, L., Ebeling, C., Turner, S. K., Westaway, D., Younkin, S., Ashe, K. H., Carlson, G. A., and Iadecola, C. (2000b). Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc. Natl. Acad. Sci. U.S.A. 97:9735-9740.
36. Price, D. L., and Sisodia, S. S. (1998). Mutant genes in familial Alzheimer's disease and transgenic models. Annu. Rev. Neurosci. 21:479-505.
37. Prohovnik, I., Mayeux, R., Sackeim, H. A., Smith, G., Stern, Y., and Alderson, P. O. (1988). Cerebral perfusion as a diagnostic marker of early Alzheimer's disease. Neurology 38:931-937.
38. Reiman, E. M., Caselli, R. J., Chen, K., Alexander, G. E., Bandy, D., and Frost, J. (2001). Declining brain activity in cognitively normal apolipoprotein E varepsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 98:3334-3339.
39. Selkoe, D. J. (2001). Alzheimer's disease: Genes, proteins, and therapy. Physiol. Rev. 81:741-766.
40. Shimohama, S., Tanino, H., Kawakami, N., Okamura, N., Kodama, H., Yamaguchi, T., Hayakawa, T., Nunomura, A., Chiba, S., Perry, G., Smith, M. A., and Fujimoto, S. (2000). Activation of NADPH oxidase in Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 273:5-9.
41. Simonian, N. A., and Coyle, J. T. (1996). Oxidative stress in neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol. 36:83-106.
42. Small, G. W., Ercoli, L. M., Silverman, D. H., Huang, S. C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., Mazziotta, J. C., Saxena, S., Wu, H. M., Mega, M. S., Cummings, J. L., Saunders, A. M., Pericak-Vance, M. A., Roses, A. D., Barrio, J. R., and Phelps, M. E. (2000). Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 97:6037-6042.
43. Smith, C. D., Andersen, A. H., Kryscio, R. J., Schmitt, F. A., Kindy, M. S., Blonder, L. X., and Avison, M. J. (1999). Altered brain activation in cognitively intact individuals at high risk for Alzheimer's disease. Neurology 53:1391-1396.
44. Smith, M. A., Richey, H. P., Sayre, L. M., Beckman, J. S., and Perry, G. (1997). Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17:2653-2657.
45. Stewart, R., Cai, H., Harrison, D. G., Rothe, G., and Valet, G. (1998). Cardiovascular factors in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry. 65:143-147.
46. Thomas, T., Thomas, G., McLendon, C., Sutton, T., and Mullan, M. (1996). β-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380:168-171.
47. Vinters, H. V., Wang, Z. Z., and Secor, D. L. (1996). Brain parenchymal and microvascular amyloid in Alzheimer's disease. Brain Pathol. 6:179-195.
48. Wilson, C. A., Doms, R. W., and Lee, V. M. (1999). Intracellular APP processing and A beta production in Alzheimer disease. J. Neuropathol. Exp. Neurol. 58:787-794.
49. Wolin, M. S. (2000). Interactions of oxidants with vascular signaling systems. Arterioscler Thromb. Vasc. Biol. 20:1430-1442.
50. Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., Migheli, A., Nawroth, P., Stern, D., and Schmidt, A. M. (1996). RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382:685-691.
51. Zhang, F., Eckman, C., Younkin, S., Hsiao, K. K., and Iadecola, C. (1997). Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein. J. Neurosci. 17:7655-7661.